NEW YORK, NY / ACCESS Newswire / December 14, 2025 / If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ:MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://stockdropcenter.com/moonlake-lawsuit-submission-form?prid=180233&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

NEW YORK, NY / ACCESS Newswire / December 14, 2025 / If you suffered a loss on your Firefly Aerospace Inc. (NASDAQ:FLY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://shareholderclaimcenter.com/firefly-aerospace-inc.-lawsuit-submission-form?prid=180245&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / December 14, 2025 / If you suffered a loss on your James Hardie Industries plc. (NYSE:JHX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://shareholderclaimcenter.com/james-hardie-industries-plc.-lawsuit-submission-form?prid=180242&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Blue Owl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Blue Owl between February 6, 2025 and November 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi

NEW YORK, NY / ACCESS Newswire / December 14, 2025 / If you suffered a loss on your Telix Pharmaceuticals Ltd. (NASDAQ:TLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://investorclaimform.com/telix-pharmaceuticals-ltd.-lawsuit-submission-form?prid=180232&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) — Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration (TGA) to manufacture the Company's proprietary high-density microarray patch (HD-MAP) for clinical trials at its state-of-the-art biomedical facility in Brisbane. This achievement strengthens Vaxxas' leadership in next-generation vaccine

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery GlobeNewswire December 14, 2025 BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) — Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration (TGA) to manufacture

DUBAI, United Arab Emirates, Dec. 14, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM), an Ethereum-based DeFi crypto project, has confirmed that independent security reviews by Halborn Security are ongoing as part of its preparation for the upcoming V1 release. The update comes as the project continues to progress through its development roadmap and presale phases,

Ethereum-Based Mutuum Finance (MUTM) Confirms Ongoing Halborn Security Reviews Ahead of V1 Launch GlobeNewswire December 14, 2025 DUBAI, United Arab Emirates, Dec. 14, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM), an Ethereum-based DeFi crypto project, has confirmed that independent security reviews by Halborn Security are ongoing as part of its preparation for the upcoming V1

New York, New York–(Newsfile Corp. – December 14, 2025) – Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the